Excited to announce the launch of Fauna Brain™, a proprietary AI platform designed to accelerate target discovery and streamline early-stage R&D. The platform represents a major evolution of Fauna Bio’s Convergence™ discovery engine. 🧬🧬
https://t.co/co5o1Owd6q
Congrats to our co-founders @ashleyz413@krgrabek and @LindaBGoodman for being named to this year’s @Inc Female Founders 500 list! 🌟
See the full list:
https://t.co/d50iYpiIOx
Our CEO & Co-Founder @ashleyz413 on the SIC Ventures and @StanfordMed event at #JPM25. Great discussion with female execs discussing raising funding for their biotech. 🧬🧬
Our CEO & Co-Founder @ashleyz413 will be speaking at the @StanfordMed SIC Venture Studio next Tuesday Jan 14, 11.30 am PT during #JPM25 Healthcare Conference. 🧬🧬
Register to attend:
👇👇
https://t.co/iOFdkZupvt
We’re excited to select Faun1083 as our first development candidate. Discovered through our proprietary Convergence™ drug discovery platform, Faun1083 is a potential first-in-class therapeutic targeting heart failure with preserved ejection fraction. 🧬
https://t.co/yTadlIVk9d
📣 Speaker Announcement!
We’re excited to announce that Ashley Zehnder, Co-Founder & CEO at Fauna Bio will be speaking at Biotech Showcase 2025!
Find out more about what is in store at Biotech Showcase >> https://t.co/ApGV1AEfSC
#BiotechShowcase#Biotech#Financing
Ashley Zehnder @faunabio discusses the insights that can be gleaned from the genetics of hibernating animals, the human health conditions that might be addressed with the approach, and the company’s deal with Eli Lilly to discover new obesity drugs.
https://t.co/5MDMn5cXBx
.@neiltyson, Chuck Nice, and Gary O’Reilly team up with Ryan Sprenger, Senior Research Scientist at Fauna Bio, to explore a question straight out of science fiction: can humans #hibernate in space like animals do on Earth? @StarTalkRadio 🌎🪐
Watch here:
https://t.co/JBo28cHTyd